A major obstacle has been the limited availability of immune-aging models that are both predictive and experimentally tractable. Conventional in vitro systems often fail to capture the tissue context, cellular crosstalk, and microenvironmental cues that govern when and how immune responses ignite. As a result, “aging phenotypes” can be difficult to reproduce across laboratories and difficult to connect to causal pathways.

In a 2026 Nature Aging discussion, Nikolich and colleagues argue that the field needs a shift from descriptive comparisons toward engineered, mechanistically grounded platforms. They propose multidisciplinary strategies spanning immunology, gerontology, and engineering to interrogate immune aging at the point of initiation—when innate sensors, tissue barriers, and early signaling networks collectively determine the trajectory of downstream immunity.

The authors highlight drug delivery technologies as a route to more precise interventions. By tuning where, when, and at what dose immunomodulatory agents act, researchers could better test how age-altered signaling thresholds change the balance between protective responses and harmful inflammation.

They also emphasize extracellular matrix (ECM) and biomaterials, noting that aging reshapes the physical and biochemical scaffold surrounding immune cells. Biomaterials that recapitulate age-associated stiffness, ligand density, and degradation dynamics could reveal how microenvironmental cues reprogram immune recruitment, activation, and effector function.

Microphysiological systems and organoid-like models are presented as complementary engines for causality. These platforms can integrate multiple cell types, enable controlled perturbations, and better mimic tissue architecture than traditional culture formats.

Together, these approaches aim to deliver validated in vitro tools for immune-aging research—tools designed not only to measure differences, but to reproduce them reliably and connect them to specific upstream drivers.

The ultimate ambition is precision diagnostics and therapies that can “reprogram and rejuvenate” immune function in older adults, extending both lifespan and healthspan. By targeting immune-response initiation with engineered models, the field may finally bridge the gap between observational aging biology and interventions that work.

Subject of Research: Aging immune system; immune response initiation models and modulation

Article Title: Bioengineering strategies to interrogate and modulate the aging immune system

Article References: Nikolich, J.Ž., Wolf, M.T., Pompano, R.R. et al. Bioengineering strategies to interrogate and modulate the aging immune system. Nat Aging (2026). https://doi.org/10.1038/s43587-026-01187-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s43587-026-01187-y

At the heart of this breakthrough lies the integration of two complex biological data sets: the IgG N-glycome and the blood transcriptome. The IgG N-glycome pertains to the intricate sugar structures covalently attached to immunoglobulin G (IgG) antibodies. These glycan modifications play key roles in immune function and have been shown to evolve with age, reflecting immune system remodeling and systemic physiological changes. On the other hand, the transcriptome captures a snapshot of active gene expression within blood cells at any given moment, offering a dynamic overview of cellular activity and responses to internal and external stimuli. By examining these two layers together, the researchers aimed to encapsulate a more holistic fingerprint of biological aging.

Developing a tool capable of synergizing these complex data types was a formidable challenge, expertly addressed through the application of Deep Reinforcement Learning, a sophisticated form of artificial intelligence where algorithms iteratively learn optimal decision-making strategies from interacting with the data environment. This approach led to the creation of an ageing clock dubbed “gtAge,” a model that comprehensively interprets multi-omics inputs to predict biological age. Dr Xingang Li, a leading co-author and Postdoctoral Research Fellow at ECU, elucidated that gtAge can predict chronological age with a remarkable 85.3% accuracy, substantially surpassing previous models that relied solely on either glycomic or transcriptomic data.

The implications of this enhanced precision are profound. The model calculates what is known as the “delta age,” the discrepancy between predicted biological age and actual chronological age. This delta age correlates significantly with well-established markers of health and aging, including cholesterol levels, glucose metabolism, and other cardiovascular and metabolic indicators. Such linkage suggests that gtAge not only measures aging but also provides an actionable metric related to an individual’s real health risks, offering a potential early diagnostic tool for age-associated diseases.

Dr Li highlighted the critical limitation of relying exclusively on chronological age, pointing out its inability to capture the heterogeneity in aging observed across individuals. While some people experience pronounced physical and cognitive decline in their 60s or 70s, others maintain robust health well into nonagenarian years. This variation is attributable to differences in biological age driven by genetics, lifestyle, nutritional status, and disease history, emphasizing the need for a metric like gtAge that reflects these nuanced factors.

The development of gtAge also underscores a triumph of interdisciplinary collaboration. ECU’s Dr Syed Islam, a Senior Lecturer in Computer Science, led the AI methodology. His team engineered a custom AI tool named “AlphaSnake,” which harnesses Deep Reinforcement Learning to intelligently select the most informative features from the multi-omics datasets, avoiding the traditional pitfalls of naïvely merging heterogeneous data. The algorithm effectively navigates the complex biological landscape, balancing signal extraction while minimizing noise and redundancy, thus optimizing the age prediction model.

Testing the model rigorously, the researchers applied gtAge to a cohort of 302 middle-aged adults participating in the Busselton Healthy Ageing Study in Western Australia. This study population provided a valuable landscape to evaluate the tool’s robustness across a typical demographic range. Findings demonstrated that gtAge not only reflected chronological age with high fidelity but also linked with biological markers indicative of health status, reinforcing its potential clinical utility.

In context, Australia’s population dynamics—marked by rising elderly demographics—amplify the relevance of such a tool. The ability to assess biological age precisely allows healthcare practitioners to identify patients at elevated risk of age-dependent disorders earlier, enabling timely intervention strategies that could delay or prevent disease onset. Dr Islam emphasized the prospective public health benefits, where early lifestyle modifications informed by biological age measurements could markedly improve quality of life and reduce healthcare burdens.

Importantly, the concept of an aging clock is not new, yet previous iterations struggled with limited accuracy, often due to reliance on single data types or insufficient integration methods. The gtAge clock sets a new benchmark by leveraging multi-omics integration facilitated through a novel AI framework, thus providing a richer, more accurate picture of aging biology that captures the multifaceted nature of the process.

Beyond predicting age, this multifactorial approach opens the door for uncovering mechanisms that drive aging at a molecular level. The integration of glycomic and transcriptomic data provides insights into immune modulation, inflammatory status, and genetic regulation affecting aging pathways. Such mechanistic understanding could inform drug discovery, therapeutic targeting, and the design of personalized anti-aging interventions.

Looking forward, the research team envisions expanding the utility of gtAge through larger, more diverse population studies and longitudinal tracking to monitor how biological age changes over time in response to interventions. This could enrich its predictive power and verify its role as a dynamic health biomarker. Furthermore, integrating additional omics layers, such as proteomics or metabolomics, may refine and enhance the model’s sensitivity and specificity.

The study detailing this advance, titled “Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome,” was published in the journal Engineering on August 19, 2025. The authors’ transparent declaration asserts no competing financial interests, affirming the integrity of their findings.

In summary, this transformative work represents a milestone in aging research and precision medicine. As technologies converge and sophisticated AI models emerge, tools like gtAge provide an empowering lens for clinicians and individuals alike to understand biological aging beyond the passage of time. By translating complex biological data into meaningful health insights, this innovation holds the promise of fostering healthier lifespans and reshaping ageing from an inevitable decline to a manageable, informed journey.

Subject of Research: Cells

Article Title: Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome

News Publication Date: 19-Aug-2025

Web References:
https://www.sciencedirect.com/science/article/pii/S2095809925004837?via%3Dihub
http://dx.doi.org/10.1016/j.eng.2025.08.016

References:
Li, X., Islam, S., Xia, Y., Baten, A., Tan, X., & Wang, W. (2025). Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome. Engineering. https://doi.org/10.1016/j.eng.2025.08.016

Keywords:
Biological age, Aging clock, IgG N-glycome, Blood transcriptome, Deep reinforcement learning, Multi-omics integration, Artificial intelligence, Machine learning, Precision medicine, Age-related diseases

The immune system is a dynamic network composed of various cell types that protect the body from infection and maintain homeostasis. With age, however, the immune system undergoes gradual deterioration, known as immunosenescence—a decline marked by reduced naïve T cell output, diminished thymic function, and altered inflammatory profiles. While immunosenescence has traditionally been viewed as a consequence of aging alone, this pioneering study demonstrates that features of premature immune ageing can be detected in individuals exhibiting early joint pain and undifferentiated arthritis, conditions often preceding RA diagnosis. This suggests that immune ageing may serve as a direct mechanistic contributor to disease pathogenesis rather than an incidental occurrence.

The study evaluated a diverse cohort of 224 participants, spanning individuals with joint discomfort to those with established rheumatoid arthritis. Utilizing advanced immune profiling techniques, investigators quantitatively assessed markers of immune ageing, including the notoriously informative IMM-AGE score—a composite measure indexing immune system decline across multiple dimensions. Patients exhibiting elevated IMM-AGE measurements prior to RA diagnosis displayed significant reductions in their populations of naïve T cells, a hallmark of thymic involution, alongside an upregulation of key inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), and C-reactive protein (CRP). These molecular signatures collectively portray an immune landscape primed for aberrant inflammatory responses.

Crucially, the research delineated a temporal progression of immune system alterations linked to RA development. While early immune ageing features were evident before clinical diagnosis, more advanced cellular ageing markers—such as the abundance of senescent T cells and elevated Th17 cell populations—appeared predominantly in those with fully established disease. Senescent immune cells lose proliferative capacity and secrete pro-inflammatory factors, exacerbating tissue damage and fueling chronic inflammation central to RA pathology. The Th17 subset, known for its potent inflammatory properties, is implicated in driving joint destruction through secretion of interleukin-17, further underlining the evolving immune dysfunction as RA progresses.

These insights into the immunologic timeline of RA have profound therapeutic implications. Traditionally, treatments have focused on managing symptoms and suppressing excessive immune activity once clinical signs manifest. This new evidence, however, points toward the tantalizing possibility of intercepting RA at its inception by targeting mechanisms of premature immune ageing. Interventions designed to bolster immune resilience or decelerate cellular ageing pathways could revolutionize RA management and prevention.

Among prospective therapeutic strategies are agents that stimulate autophagy—the body’s intrinsic process for degrading and recycling damaged cellular components. Autophagy enhancement may mitigate the accumulation of senescent cells and reduce inflammatory burden. Spermidine, a naturally occurring polyamine shown to activate autophagy, emerges as a promising candidate based on preclinical models. Likewise, senolytic drugs capable of selectively clearing senescent cells have gained traction in ageing research and could ameliorate the pro-inflammatory milieu underpinning RA development.

Furthermore, metformin, a widely prescribed anti-diabetic medication known to attenuate low-grade inflammation and support autophagy, is being explored for its immunomodulatory effects beyond glucose regulation. Its potential to modulate ageing-associated immune dysfunction adds to a growing repertoire of geroprotective interventions that may offer dual benefits in chronic inflammatory diseases such as RA.

The study’s senior author, Dr. Niharika Duggal, an Associate Professor specializing in Immune Ageing at the University of Birmingham, emphasizes the paradigm shift enabled by these findings. She notes, “Our work provides compelling evidence that immune ageing is not a passive consequence but a potentially active driver in the pathogenesis of rheumatoid arthritis. Identifying these ageing signatures early, even before clinical symptoms fully develop, opens the door to innovative treatments aimed at delaying or preventing disease onset.”

This investigation also highlights the value of the IMM-AGE scoring system as a predictive biomarker tool. By quantifying immune ageing dynamics, clinicians may soon be able to identify individuals at high risk of RA well before joint destruction occurs, allowing for targeted interventions tailored to immunological profiles rather than waiting for symptomatic presentation.

The research was supported by FOREUM and the European League Against Rheumatism (EULAR), reflecting a collaborative international commitment to unraveling complex immune mechanisms underlying inflammatory diseases. The methodological rigor of the study, involving detailed immune phenotyping and longitudinal assessment at multiple disease stages, marks a milestone in autoimmune research.

Given the morbidity and societal burden associated with rheumatoid arthritis—a chronic disease characterized by joint inflammation, pain, and progressive disability—any advancement toward pre-emptive treatment strategies carries enormous clinical relevance. These findings not only deepen scientific understanding of immune dysregulation in RA but also chart new avenues for interdisciplinary research at the intersection of immunology, gerontology, and rheumatology.

As exploration into geroprotective drugs advances, future clinical trials targeting autophagic pathways, senescent cell clearance, and inflammatory modulation will be instrumental in translating these insights into tangible therapeutic benefits. This study lays the foundational framework for a new era of personalized medicine, where the ageing immune system is both a biomarker and therapeutic target in rheumatoid arthritis.

In conclusion, the University of Birmingham’s study presents compelling evidence that features of premature immune ageing emerge well before rheumatoid arthritis manifests clinically. These findings fundamentally challenge prevailing notions that immune ageing results solely from chronic inflammation in RA and instead propose that accelerated immune senescence initiates the pathological cascade. By leveraging this knowledge, the scientific and medical communities move closer to intercepting RA in its nascent stages, potentially preventing the widespread tissue damage and functional impairment that have long defined the disease’s clinical course.

Subject of Research: Immune system ageing in the development and pathogenesis of rheumatoid arthritis

Article Title: Specific Features of Immune Ageing are Detected in the Earliest Stages in Rheumatoid Arthritis Development

News Publication Date: 3-Sep-2025

Web References:
10.1016/j.ebiom.2025.105900

Keywords: Rheumatoid arthritis, immune ageing, immunosenescence, autophagy, senescent cells, inflammatory markers, IMM-AGE score, IL-6, TNFα, CRP, Th17 cells, geroprotective drugs, senolytics, metformin

The investigation spearheaded by Dr. Rebecca Hesterberg and her team in Moffitt’s Department of Tumor Microenvironment and Metastasis focused on the intricate ways in which B cell lymphoma modulates immune cell function. T cells, a critical subset of immune cells responsible for targeting and eliminating pathogens and malignant cells, were shown to undergo dramatic transformations in the presence of lymphoma. Remarkably, young, healthy T cells began to exhibit molecular and functional features characteristic of aged cells, an effect measured by markers such as chronic inflammation, disrupted proteostasis, and impaired iron homeostasis.

At a molecular level, the study painstakingly mapped out how lymphoma exposure causes T cells to accumulate excess iron, which in turn renders them resistant to ferroptosis—a form of programmed cell death dependent on iron and lipid peroxidation. Ferroptosis resistance enables these dysfunctional T cells to escape normal cellular turnover, potentially leading to permanent immune dysfunction. Alongside iron overload, impaired protein quality control mechanisms were observed, a hallmark phenomenon associated with cellular senescence and organismal aging. These findings constitute compelling evidence that the lymphoma milieu drives a premature aging program within immune cells.

Further examination revealed that the aging effects induced by lymphoma extend well beyond the immune system. The researchers detected hallmark signs of accelerated aging in vital organs such as blood vessels, kidneys, and intestines in animal models. This systemic aging phenotype points to a cancer-driven, body-wide remodeling that likely exacerbates the frailty and comorbidities often observed in lymphoma patients. The dismantling of tissue homeostasis in multiple organs presents a concerning picture of cancer as a disruptor of overall organismal integrity and metabolic health.

Importantly, this study challenges the long-standing dogma that the accelerated aging commonly seen in cancer patients primarily arises as a side effect of toxic therapies such as chemotherapy and radiation. While these treatments do cause cellular damage and functional decline, the researchers demonstrated that the lymphoma itself can independently instigate immune and tissue aging. This uncoupling of cancer-related aging from treatment effects pushes the scientific community to reconsider how we assess and manage survivorship and long-term health in lymphoma patients.

Dr. John Cleveland, Ph.D., Chief Scientific Officer at Moffitt and senior author of the study, emphasized the clinical significance of these findings, stating, “Cancer doesn’t exist in isolation; it modifies the patient’s entire biological landscape. Our data show that lymphoma alone is sufficient to trigger systemic aging markers, explaining why many patients experience age-related symptoms irrespective of treatment.” This understanding paves the way for more nuanced therapeutic approaches that target not only cancer cells but also the broader physiological disruptions caused by the disease.

One of the most promising revelations from the research is that many of the aging-like changes instigated by lymphoma are not irreversible. Experimental models demonstrated that removing tumors resulted in the partial rescue of immune and tissue function, suggesting that these aging processes can be therapeutically modulated. This raises exciting possibilities for developing adjunct treatments aimed at restoring healthy cellular function and mitigating premature aging symptoms in lymphoma patients.

The study leveraged cutting-edge observational methodologies to analyze immune cells and tissue samples from both human subjects and animal models. Using multi-omics profiling—including transcriptomics, proteomics, and metabolomics—the team delineated the complex network of biological pathways perturbed by lymphoma. Chronic inflammation, or “inflammaging,” emerged as a central driver of the observed phenotypes, linking tumor presence with systemic immune activation and cellular decline. Such integrated systems biology approaches are critical for unraveling the multifaceted impact of cancer on the host.

On a broader scale, these discoveries invite reflection on the intersection of cancer biology and gerontology. With global populations aging rapidly and cancer incidence rising exponentially with age, understanding how tumors accelerate tissue senescence may inform preventative strategies and improve patient quality of life. The reciprocal relationship between aging and cancer initiation and progression becomes more evident, underscoring the need for research at this interface.

The financial and institutional support behind this effort—from the National Institutes of Health to collaborative organizations such as the Leukemia and Lymphoma Society and the Florida Department of Health—highlights the importance of multidisciplinary funding in tackling complex biomedical challenges. This study exemplifies how sustained investment in translational research yields insights with broad implications for public health.

Looking ahead, the team advocates for deeper mechanistic studies to identify specific molecular targets within the lymphoma-driven aging axis. Therapeutics designed to modulate iron metabolism, enhance proteostasis, or quell chronic inflammation could revolutionize cancer treatment paradigms. Addressing the systemic effects of lymphoma offers a dual benefit: more effective oncologic control and healthier survivorship, free from the debilitating consequences of premature aging.

In conclusion, the revelation that lymphoma accelerates T cell and tissue aging marks a transformative stride in cancer biology. It reframes tumors as active agents of systemic physiological remodeling rather than localized proliferative anomalies alone. This new understanding demands integration into clinical management and inspires hope for innovative therapies that safeguard immune function and organ vitality during and after cancer.

Subject of Research: People
Article Title: Lymphoma accelerates T cell and tissue aging
News Publication Date: August 21, 2025
Web References:

• https://www.moffitt.org/
• https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/
• https://www.sciencedirect.com/science/article/pii/S1535610825003290
  References:
• DOI: 10.1016/j.ccell.2025.07.023
  Keywords: T lymphocytes, lymphoma, immune aging, ferroptosis resistance, iron metabolism, proteostasis, inflammaging, tissue senescence

The thymus serves as the quintessential “school” for T-cells, educating immature lymphocytes to distinguish between harmful pathogens and the body’s own tissues. This education ensures immune tolerance and prevents autoimmunity. However, with advancing age, thymic involution—a process of progressive shrinking—leads to a sharp decline in new T-cell output. This atrophy underpins a weakened immune repertoire and is implicated in higher susceptibility to infectious diseases, poor tumor surveillance, and compromised response to immunizations observed in elderly populations.

Central to the study is FGF21, a peptide hormone traditionally recognized for its metabolic effects, including regulation of glucose and lipid metabolism. Untapped until now, FGF21 has been identified as a potent thymic regulator that modulates the tissue’s architecture and function. Using advanced mouse models, researchers demonstrated that increasing systemic FGF21 levels can preserve both the size and function of the thymus. This preservation is evidenced by sustained thymic morphology and enhanced generation of a diverse T-cell population, even in aged animals.

Mechanistically, the investigators revealed that FGF21 operates through paracrine signaling to influence the stromal microenvironment of the thymus. These stromal cells, including specialized “labyrinth-shaped” fibroblasts, provide structural and biochemical cues essential for T-cell maturation. FGF21’s impact on these stromal compartments realigns thymic tissue morphology, maintaining the gland’s capacity to support robust immunopoiesis. Importantly, FGF21 appears to modulate the mechanistic Target Of Rapamycin (mTOR) signaling pathway internally, a crucial nutrient-sensing cascade implicated in cellular growth and senescence, thereby dynamically tuning thymic output in response to physiological needs.

The implications of this research extend beyond thymic size; FGF21 also mitigates age-associated inflammation, a chronic low-grade immune activation state commonly referred to as “inflammaging.” By promoting thymic output and enhancing central tolerance mechanisms that eliminate self-reactive T-cells, FGF21 reduces the risk of autoimmune reactions, which increase as thymic function wanes. This hormone thus plays a dual role—preserving immune competence while restoring immunological self-restraint.

Director of the study, Dr. Ann Griffith, articulated the transformative potential of these findings. “Our results unveil FGF21 as a key molecular target to durably restore thymic function, and by extension, revitalizing the aging immune system,” she stated. “The capacity to modulate mTOR signaling within the thymic microenvironment provides us with a novel axis to combat thymic atrophy, which has long been a barrier to healthy aging.”

This research builds on previous transcriptomic analyses revealing genomic shifts linked to thymic regeneration, where FGF21 expression correlated strongly with tissue growth and regeneration markers. The newfound mechanistic insights position FGF21 as not just a metabolic regulatory hormone but as a linchpin in immune system maintenance.

Despite these encouraging advancements, the authors caution that FGF21 augmentation slows, but does not entirely prevent, thymic involution—suggesting that combined therapeutic strategies may be necessary for comprehensive restoration of immune homeostasis. Future work aims to unravel how FGF21 interacts with other thymic factors and systemic metabolic cues, and to assess translational possibilities in human clinical settings.

The broader biomedical community is enthusiastic about these findings, as thymic decline has been a challenging obstacle limiting the efficacy of immunotherapies and vaccines in aging populations. Strategies enhancing thymopoiesis, such as FGF21-based approaches, may revolutionize geriatric medicine by fortifying immune defenses against emerging infectious threats and age-related malignancies.

Moreover, the hormone’s role in dampening autoimmunity opens exciting prospects for autoimmune disease management. By reinstating central tolerance mechanisms, FGF21 could help recalibrate immune recognition—potentially benefiting conditions like rheumatoid arthritis, lupus, and multiple sclerosis.

This discovery is exemplary of how the intersection of molecular endocrinology and immunology offers novel paths to mitigating the biological toll of aging. As the global demographic shifts toward older populations, preserving immune function is paramount—not only to extend lifespan but to enhance healthspan and quality of life.

In summary, the UT Health San Antonio team’s investigation into FGF21 unveils a pivotal molecular orchestrator capable of modulating thymic size, cellular architecture, and immune education. Their comprehensive work underscores the intertwined relationship between metabolic hormones and immune competence and opens the door to innovative therapeutic avenues aiming to sustain immune resilience well into advanced age.

Subject of Research: Preservation of thymic function and immune system aging via FGF21 regulation

Article Title: Paracrine FGF21 dynamically modulates mTOR signaling to regulate thymus function across the lifespan

News Publication Date: May 1, 2025

Web References:

• UT Health San Antonio
• Nature Aging Article
• Full News Story

References:
Griffith, A. et al. "Paracrine FGF21 dynamically modulates mTOR signaling to regulate thymus function across the lifespan." Nature Aging (2025).

Keywords: Immune system, Thymus, FGF21, T-cells, Aging, mTOR signaling, Immunosenescence, Autoimmunity, Inflammation, Thymic regeneration, Molecular biology, Immunology